Ultragenyx Finalizes $203M Priority Review Voucher Sale, Down from $210M
RARE sits 17% above its 52-week low of $12.73.
Summary
Ultragenyx agreed to sell its Priority Review Voucher for $203 million cash, down from the $210 million previously disclosed, with closing subject to HSR clearance.
Key Events · M&A and Partnerships · RARE
-
PRV Sale Price Reduced to $203M
The asset purchase agreement sets the purchase price at $203 million in cash, a $7 million reduction from the $210 million disclosed on October 7, 2026.
-
Non-Dilutive Capital Infusion
The sale provides $203 million in cash proceeds without issuing new shares, strengthening the balance sheet following recent FDA approvals for FAYUVI and GENGLYCOS.
-
HSR Antitrust Clearance Required
Closing is conditioned on expiration or termination of the Hart-Scott-Rodino waiting period, a standard regulatory step for transactions of this size.
-
Agreement Filed with 10-K
The full PRV Asset Purchase Agreement will be filed as an exhibit to the company's Annual Report on Form 10-K for the year ended December 31, 2026.
Analysis · RARE · Life Sciences
Ultragenyx has entered into a definitive asset purchase agreement to sell its FDA-awarded Priority Review Voucher for $203 million in cash, a $7 million reduction from the $210 million figure disclosed a week earlier. The transaction remains subject to HSR antitrust clearance and customary closing conditions. The sale provides meaningful non-dilutive capital following the company's recent regulatory wins, though the lower price suggests some negotiation concessions.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 29.3% of the 1486 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RARE was trading at $14.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.73 to $39.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.